Effect of combined contraceptive pill on immune cell of ovarian endometriotic tissue

Not Applicable

Completed

• Conditions: Patients with ovarian endometriotic cyst Combined oral contraceptive pill; Endometriotic cysts; Combined oral contraceptive pill

• Registration Number: TCTR20170425001
• Lead Sponsor: Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-04-25
• Study Completion: 2017-08-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 44

Inclusion Criteria

1.Healthy female subjects age 18-45 years old.
2.Subjects who were diagnosed with endometriotic cyst with size equal or more than 3 centimeters.
3.Subjects who have no previous records of taking any kinds of hormones during 3 months prior to the study and those who were not recieved depot-medroxyprogesterone acetate (DMPA) or GnRHa within 9 months prior to the study.
4.Subjects who have no limitations in taking either ethinyl estradiol with Desogestrel.
5.Subjects who are willing to participate in the study program.

Exclusion Criteria

1.Subjects with underlying disease that contraindicate to receive ethinyl estradiol and desogestrel such as Cirrhosis, Chronic kidney disease, Coagulopathy, Heart disease and Pulmonary disease.
2.Subjects who have contraindication to taking either ethinyl estradiol and desogestrel
3.Subjects who are intolerable to irregularity of menstruation cycle.
4.Subjects who rejected or withdrew from the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of macrophages 1 month Immunohistochemistry

Secondary Outcome Measures

Name	Time	Method
umber of FoxP3 cells 1 month Immunohistochemistry,Number of NK cells 1 month Immunohistochemistry